Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Safety and Performances of the LINEA Cardiac Pacing Lead Optimized for the Implantation in Interventricular Septum

NCT: NCT07342608 · RECRUITING

NCT IDNCT07342608
StatusRECRUITING
Start Date2026-06-23
Completion2030-04-30
SponsorMicroPort CRM (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.

Frequently Asked Questions

What is Safety and Performances of the LINEA Cardiac Pacing Lead Optimized for the Implantation in Interventricular Septum?

Safety and Performances of the LINEA Cardiac Pacing Lead Optimized for the Implantation in Interventricular Septum is a clinical trial registered under NCT07342608. Current status: RECRUITING.

What is the status of NCT07342608?

The current status of NCT07342608 (Safety and Performances of the LINEA Cardiac Pacing Lead Optimized for the Implantation in Interventricular Septum) is: RECRUITING.

When did Safety and Performances of the LINEA Cardiac Pacing Lead Optimized for the Implantation in Interventricular Septum start?

Safety and Performances of the LINEA Cardiac Pacing Lead Optimized for the Implantation in Interventricular Septum started on 2026-06-23.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑